These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 17716136)

  • 41. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality.
    Undas A; Kolarz M; Kopeć G; Tracz W
    Nephrol Dial Transplant; 2008 Jun; 23(6):2010-5. PubMed ID: 18156458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
    Nielsen VG
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes in clot lysis levels of reteplase and streptokinase following continuous wave ultrasound exposure, at ultrasound intensities following attenuation from the skull bone.
    Härdig BM; Carlson J; Roijer A
    BMC Cardiovasc Disord; 2008 Aug; 8():19. PubMed ID: 18727834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sonothrombolysis: the contribution of stable and inertial cavitation to clot lysis.
    Petit B; Bohren Y; Gaud E; Bussat P; Arditi M; Yan F; Tranquart F; Allémann E
    Ultrasound Med Biol; 2015 May; 41(5):1402-10. PubMed ID: 25601463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
    Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
    Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
    Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amino-Terminal Fusion of Epidermal Growth Factor 4,5,6 Domains of Human Thrombomodulin on Streptokinase Confers Anti-Reocclusion Characteristics along with Plasmin-Mediated Clot Specificity.
    Maheshwari N; Kantipudi S; Maheshwari A; Arora K; Vandana ; Kwatra N; Sahni G
    PLoS One; 2016; 11(3):e0150315. PubMed ID: 26974970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clot-targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis.
    Cabrera D; Eizadi Sharifabad M; Ranjbar JA; Telling ND; Harper AGS
    J Thromb Haemost; 2022 Nov; 20(11):2556-2570. PubMed ID: 35950914
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Translational initiatives in thrombolytic therapy.
    Klegerman ME
    Front Med; 2017 Mar; 11(1):1-19. PubMed ID: 28116631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in thrombolytics for treatment of acute ischemic stroke.
    Kirmani JF; Alkawi A; Panezai S; Gizzi M
    Neurology; 2012 Sep; 79(13 Suppl 1):S119-25. PubMed ID: 23008386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fibrinolytic profiles in local low-dose thrombolysis with streptokinase and recombinant tissue plasminogen activator.
    Berridge DC; Earnshaw JJ; Westby JC; Makin GS; Hopkinson BR
    Thromb Haemost; 1989 Apr; 61(2):275-8. PubMed ID: 2501898
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultrasound has synergistic effects in vitro with tirofiban and heparin for thrombus dissolution.
    Birnbaum Y; Atar S; Luo H; Nagai T; Siegel RJ
    Thromb Res; 1999 Dec; 96(6):451-8. PubMed ID: 10632468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound.
    Kawata H; Uesugi Y; Soeda T; Takemoto Y; Sung JH; Umaki K; Kato K; Ogiwara K; Nogami K; Ishigami K; Horii M; Uemura S; Shima M; Tabata Y; Saito Y
    J Am Coll Cardiol; 2012 Dec; 60(24):2550-7. PubMed ID: 23158532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cloning and expression of hybrid streptokinase towards clot-specific activity.
    Buniya HK; Murugan V; Thangadurai C
    J Microbiol Methods; 2014 Mar; 98():84-8. PubMed ID: 24440164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix.
    Sivaraman B; Sylvester A; Ramamurthi A
    Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():145-156. PubMed ID: 26652359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.